Sii Investments Inc. WI raised its stake in shares of Allergan PLC. (NYSE:AGN) by 9.8% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,499 shares of the company’s stock after buying an additional 134 shares during the quarter. Sii Investments Inc. WI’s holdings in Allergan PLC. were worth $363,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Honeywell International Inc. grew its holdings in shares of Allergan PLC. by 13.6% in the second quarter. Honeywell International Inc. now owns 168,130 shares of the company’s stock valued at $40,871,000 after purchasing an additional 20,100 shares in the last quarter. Israel Discount Bank of New York purchased a new position in shares of Allergan PLC. in the first quarter valued at $988,000. Palladium Partners LLC grew its holdings in shares of Allergan PLC. by 1.7% in the second quarter. Palladium Partners LLC now owns 31,161 shares of the company’s stock valued at $7,575,000 after purchasing an additional 523 shares in the last quarter. DekaBank Deutsche Girozentrale purchased a new position in shares of Allergan PLC. in the second quarter valued at $41,345,000. Finally, Aviva PLC grew its holdings in shares of Allergan PLC. by 2.4% in the second quarter. Aviva PLC now owns 287,455 shares of the company’s stock valued at $69,892,000 after purchasing an additional 6,722 shares in the last quarter. 82.04% of the stock is owned by institutional investors and hedge funds.
Allergan PLC. (NYSE:AGN) opened at 204.08 on Friday. Allergan PLC. has a 1-year low of $184.50 and a 1-year high of $256.80. The firm’s 50-day moving average is $216.44 and its 200 day moving average is $232.29. The stock has a market capitalization of $68.23 billion, a price-to-earnings ratio of 6.22 and a beta of 1.15.
Allergan PLC. (NYSE:AGN) last issued its earnings results on Thursday, August 3rd. The company reported $4.02 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $3.95 by $0.07. The company had revenue of $4.01 billion during the quarter, compared to analysts’ expectations of $3.95 billion. Allergan PLC. had a return on equity of 7.37% and a net margin of 79.17%. The firm’s quarterly revenue was up 8.8% on a year-over-year basis. During the same period in the prior year, the business earned $3.35 EPS. Equities analysts anticipate that Allergan PLC. will post $16.21 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which was paid on Friday, September 15th. Shareholders of record on Friday, August 18th were issued a $0.70 dividend. This represents a $2.80 annualized dividend and a yield of 1.37%. The ex-dividend date was Wednesday, August 16th. Allergan PLC.’s payout ratio is currently 9.95%.
Allergan PLC. announced that its Board of Directors has initiated a stock buyback plan on Monday, September 25th that authorizes the company to repurchase $2.00 billion in shares. This repurchase authorization authorizes the company to repurchase up to 2.8% of its stock through open market purchases. Stock repurchase plans are often an indication that the company’s leadership believes its shares are undervalued.
TRADEMARK VIOLATION NOTICE: This story was published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this story on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this story can be accessed at https://www.com-unik.info/2017/10/13/allergan-plc-agn-shares-bought-by-sii-investments-inc-wi.html.
A number of research analysts recently weighed in on AGN shares. Citigroup Inc. reissued a “buy” rating and issued a $280.00 target price on shares of Allergan PLC. in a report on Wednesday, September 20th. Royal Bank Of Canada reissued a “buy” rating and issued a $285.00 target price on shares of Allergan PLC. in a report on Wednesday, September 6th. Piper Jaffray Companies set a $227.00 target price on shares of Allergan PLC. and gave the company a “hold” rating in a report on Friday, October 6th. Cantor Fitzgerald started coverage on shares of Allergan PLC. in a report on Friday, June 16th. They issued a “neutral” rating and a $231.00 target price for the company. Finally, Cowen and Company reissued an “outperform” rating and issued a $400.00 target price on shares of Allergan PLC. in a report on Saturday, September 23rd. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and fourteen have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $271.44.
Allergan PLC. Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
What are top analysts saying about Allergan PLC.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Allergan PLC. and related companies.